These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 30769199

  • 1. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S, García-Castillo M, Bou G, Calvo J, Cercenado E, Delgado M, Pitart C, Mulet X, Tormo N, Mendoza DL, Díaz-Regañón J, Cantón R, SUPERIOR Study Group.
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M, García-Castillo M, Bofarull AM, Cantón R, CENIT Study Group.
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva D, Chaves C, Pássaro L, Paixão L, Cantón R, STEP Study Group.
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [Abstract] [Full Text] [Related]

  • 4. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H, Körber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study Group.
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK.
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [Abstract] [Full Text] [Related]

  • 11. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 15. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021.
    Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF.
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1343-1348. PubMed ID: 38775873
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program.
    Shortridge D, Pfaller MA, Castanheira M, Flamm RK.
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):158-163. PubMed ID: 29891184
    [Abstract] [Full Text] [Related]

  • 18. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bailey AL, Armstrong T, Dwivedi HP, Denys GA, Hindler J, Campeau S, Traczewski M, Humphries R, Burnham CA.
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29976590
    [Abstract] [Full Text] [Related]

  • 19. Assessment of the In Vitro Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France.
    Viala B, Zaidi FZ, Bastide M, Dumont Y, Le Moing V, Jean-Pierre H, Godreuil S.
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [Abstract] [Full Text] [Related]

  • 20. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
    Shortridge D, Duncan LR, Pfaller MA, Flamm RK.
    Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.